ORKA Oruka Therapeutics, Inc.
ORKA Oruka Therapeutics, Inc.
Healthcare · Biotechnology
Market read
POC $68.43 · VWAP $67.07 · +7.2% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, COO + 3 others sold $3.1M, Sep 15–21
Coverage
1 watchlist
ORKA Price Structure
Loading timeframes…
Peers
Every watchlist ORKA belongs to, members best 30-day change first — ORKA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Oruka Therapeutics furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. No figures from these filings are recorded here.
full note →Against street estimates
How ORKA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
ORKA research tape
18 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.